Main Article Content
Introduction: Aflibercept and ranibizumab have become the most used drugs in the treatment of wet age-related macular degeneration. Some patients; however, do not respond to aflibercept and ranibizumab treatment. Our aim was to determine whether the switch from aflibercept to ranibizumab, and then switchback, is effective in a group of patients poorly responding to aflibercept. We assessed best corrected visual acuity, central retinal thickness, and the presence of intra- and subretinal fluid (respectively).
Material and methods: We conducted a retrospective comparative case series study. Twenty eyes of 20 patients, who had no inhibition of disease activity after at least one year of treatment with aflibercept, were included in the study. If after switch to ranibizumab the response to the drug was again inadequate, we returned to aflibercept. We divided the study population into two groups: treatment- naïve and patients who had received injections before entering the Drug Program for the Treatment of Age-Related Exudative Macular Degeneration.
Results: We observed an improvement in both best corrected visual acuity and central retinal thickness parameters, but only in the treatment-naïve group. We did not observe any statistically credible effects for sub- and intraretinal fluid in the studied groups.
Conclusions: Drug conversion may be beneficial for patients poorly responding to primary therapy. Greater improvement is seen in previously untreated patients.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (firstname.lastname@example.org)
2. Yazdi MH, Faramarzi MA, Nikfar S et al. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration. Expert Opin Biol Ther. 2015; 15(9): 1349-58. http://doi.org/10.1517/14712598.2015.1057565.
3. Smit C, Wiertz-Arts K, van de Garde EM. Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study. J Comp Eff Res. 2018; 7(6): 561-7. http://doi.org/10.2217/cer-2017-0099.
4. Chandra S, Arpa C, Menon D et al. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. Eye (Lond). 2020; 34(10): 1888-96. http://doi.org/10.1038/s41433-020-0764-9.
5. Barthelmes D, Nguyen V, Daien V et al; Fight Retinal Blindness Study Group. Two year outcomes of „treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 2018; 38(1): 20-8. http://doi.org/10.1097/IAE.0000000000001496.
6. Wachtlin J, Eter N, Hasanbasic Z et al. Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study. Graefes Arch Clin Exp Ophthalmol. 2021; 259(3): 601-11. http://doi.org/10.1007/s00417-020-04803-8. Epub 2020.
7. Salcedo-Villanueva G, Feria-Anzaldo E, Romo-Aguas JC et al. Anti-VEGF treatment switch in neovascular age-related macular degeneration: a comparison of aflibercept versus ranibizumab after a single-dose switch. Int Ophthalmol. 2019; 39: 2023-31. http://doi.org/10.1007/s10792-018-1038-4.
8. Chakravarthy U, Bezlyak V, Sagkriotis A et al. Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence Presented at: 17th EURETINA Congress, September 2017, Barcelona, Spain. http://doi.org/10.1016/j.oret.2018.09.001.
9. Spooner K, Hong T, Nair R et al. Long‐term outcomes of switching to aflibercept for treatment‐resistant neovascular age‐related macular degeneration. Acta Ophthalmol. 2019; 97(5): e706-e12. http://doi.org/110.1111/aos.14046.
10. de Sá Quirino-Makarczyk L, Sainz Ugarte MF, Viana Vieira B et al. Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice. Int J Retina Vitreous. 2020; 6: 9. http://doi.org/10.1186/s40942-020-00212-5.
11. Ertan E, Doğan M, Polat O et al. Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results. Arq Bras Oftalmol. 2021. http://doi.org/10.5935/0004-2749.20210036.
12. Gale RP, Pearce I, Eter N et al. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol. 2020; 104(4): 493-9. http://doi.org/10.1136/bjophthalmol-2019-314251.
13. Koike N, Otsuji T, Tsumura A et al. Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration. Clin Ophthalmol. 2019; 13: 1247-51. http://doi.org/10.2147/OPTH.S206910.
14. Despreaux R, Cohen SY, Semoun O et al. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice. Graefes Arch Clin Exp Ophthalmol. 2016; 254(4): 639-44. http://doi.org/10.1007/s00417-015-3084-1.
15. Hara C, Wakabayashi T, Fukushima Y et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019; 257(11): 2559-69. http://doi.org/10.1007/s00417-019-04456-2.
16. Justin GA, Rapuano CJ, Pelton RW et al. Ocular Futility: How to Approach End-of-Sight Care. Ophthalmology. 2019; 126(9): 1209-11. http://doi.org/10.1016/j.ophtha.2019.06.027.
17. Senra H, Balaskas K, Mahmoodi N et al. Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration. Am J Ophthalmol. 2017; 177: 213-24. http://doi.org/10.1016/j.ajo.2017.03.005.